COVID-19 Vaccination Hesitancy in Adults With Sickle Cell Disease

NCT05998824 | Completed

• 1 other identifier: Pro00110966
• Study Type: interventional
• Target: 33
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to test an COVID-19 vaccination information video in adults with sickle cell disease. The main questions it aims to answer are why are some adults with sickle cell disease hesitant to receive COVID-19 vaccination and whether a COVID-19 vaccination information video tailored for people with sickle cell disease will reduce vaccine hesitancy. Participants will complete a brief survey before and after watching a short video with information on vaccine safety, efficacy, and the greater impact of COVID-19 infection on people with sickle cell disease.

Conditions

Sickle Cell Disease; COVID-19 Vaccine; Vaccine Hesitancy

Outcome Measures

Primary Outcomes (1)

• Vaccine hesitancy

  To assess vaccine hesitancy in patients not vaccinated for COVID-19, we will ask participants "how likely are you to get vaccinated for COVID-19 in the future?". Response options will be dichotomized into not hesitant ("likely or somewhat likely") vs neutral vs hesitant ("somewhat unlikely or not likely"). We will also assess vaccine hesitancy for people

  before and after watching video

Study Arms (1)

Adults With Sickle Cell Disease

OTHER

Age 18 years or older

Behavioral: SCD-specific COVID-19 vaccination information (SCVI) video

Interventions

SCD-specific COVID-19 vaccination information (SCVI) video BEHAVIORAL

SCD-specific COVID-19 vaccination information (SCVI) video developed by health care providers with input from a community advisory board of people with sickle cel disease and their caregivers.

Also known as: Video

Adults With Sickle Cell Disease

Eligibility Criteria

• Age: 18 Years - 100 Years
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• diagnosis of sickle cell disease

You may not qualify if:

• unable to read or understand spoken English to complete the survey

Sponsors & Collaborators

• Duke University: lead
• American Society of Hematology: collaborator

Study Sites (1)

Duke Adult Sickle Cell Program

Durham, North Carolina, 27710, United States

Location

MeSH Terms

Conditions

Anemia, Sickle Cell; Vaccination Hesitancy

Interventions

Videotape Recording

Condition Hierarchy (Ancestors)

Anemia, Hemolytic, Congenital; Anemia, Hemolytic; Anemia; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemoglobinopathies; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Vaccination Refusal; Treatment Refusal; Treatment Adherence and Compliance; Health Behavior; Behavior

Intervention Hierarchy (Ancestors)

Tape Recording; Audiovisual Aids; Educational Technology; Technology; Technology, Industry, and Agriculture; Television

Study Officials

• John Strouse, MD, PhD

  Duke University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: measurement by survey before and after intervention

Study Record Dates

• First Submitted: August 17, 2023
• First Posted: August 21, 2023
• Study Start: September 19, 2023
• Primary Completion: September 30, 2024
• Study Completion: September 30, 2024
• Last Updated: December 24, 2024

Record last verified: 2024-06

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)